Press Releases

NAPA, Calif.–(BUSINESS WIRE)–Verndari, Inc., a biopharmaceutical company transforming vaccines with next generation science and delivery technology, announced today a federal government award to support development of Verndari’s VaxiPatch™ alternative vaccine technology. The award is funded through DRIVe the (Division of Research, Innovation, and Ventures) established by the Biomedical Advanced Research and Development Authority (BARDA), under the Office of […]

VaxiPatchTM microneedle dermal patch is part of a novel vaccination system comprised of subunit antigens and adjuvants Preclinical data showed use of VaxiPatch™ microneedle dermal patch with proprietary vaccine showed significantly higher immune response at much smaller dose compared with an existing influenza vaccine, Verndari VaxiPatchTM system is being developed for application across multiple diseases Napa, CA,

Vaccine will be delivered via a dermal patch applied to skin Verndari’s VaxiPatch™ microneedle patch technology enables mass production of vaccination kits Sacramento, CA, April 29, 2020 — Verndari, Inc., a biopharmaceutical company in Napa, California, announced today it will begin preclinical testing this week of a potential COVID-19 coronavirus vaccine, which will be administered using its patented VaxiPatch™,